Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Top Stock Reports for Johnson & Johnson, NextEra & Deere
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NextEra (NEE) and Deere (DE).
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
by Mitchell Moore
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
by Zacks Equity Research
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
3 Big Biotechs Hold Growth Potential in Second Half of 2019
by Ekta Bagri
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Top Stock Reports for Deere, Las Vegas Sands & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Deere (DE), Las Vegas Sands (LVS) and Vertex (VRTX).
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Vertex Expands Collaboration With CRISPR, Acquires Exonics
by Zacks Equity Research
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
Vertex Selects Triple Combo Regimen for Regulatory Submission
by Zacks Equity Research
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.